Antibody-Drug Conjugates in Recurrent or Metastatic HNSCC: Relevant Targets, Clinical Development, and Future Prospects - Summary - MDSpire

Antibody-Drug Conjugates in Recurrent or Metastatic HNSCC: Relevant Targets, Clinical Development, and Future Prospects

  • By

  • Zhao, Hu

  • Zhang, Senxuan

  • Wang, Fang

  • Yu, Peirong

  • Li, Jin

  • Jia, Lina

  • He, Pengfei

  • Liu, Run

  • Zhang, Jian

  • Wang, KeXin

  • Han, Rui

  • Huangfu, Hui

  • May 5, 2026

  • 0 min

Share

Objective:

To review the potential of antibody-drug conjugates (ADCs) as a therapeutic strategy for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Key Findings:
  • ADCs offer selective delivery of cytotoxic drugs to cancer cells, improving therapeutic outcomes.
  • Current systemic treatments for R/M HNSCC have limited effectiveness, underscoring the need for innovative therapies.
  • Encouraging results from early and late-stage clinical trials indicate the potential of ADCs in improving patient outcomes.
Interpretation:

ADCs represent a promising advancement in the treatment of R/M HNSCC, potentially addressing the limitations of existing therapies.

Limitations:
  • The review may not cover all ongoing clinical trials or emerging ADCs.
  • Long-term efficacy and safety data for ADCs in R/M HNSCC are still needed.
Conclusion:

ADCs are a highly promising therapeutic strategy for R/M HNSCC, warranting further research and clinical exploration.

Original Source(s)

Antibody-Drug Conjugates in Recurrent or Metastatic HNSCC: Relevant Targets, Clinical Development, and Future Prospects

  • by Zhao, Hu , Zhang, Senxuan , Wang, Fang , Yu, Peirong , Li, Jin , Jia, Lina , He, Pengfei , Liu, Run , Zhang, Jian , Wang, KeXin , Han, Rui , Huangfu, Hui

  • May 5, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Biotech exec Jeremy Levin on the industry’s strategic turning point